MassChallenge

MassChallenge is a non-equity startup accelerator headquartered in Boston, Massachusetts, with additional locations in Israel, Mexico, Switzerland, Texas, and the UK. Founded in 2009, it focuses on fostering innovation and entrepreneurship by supporting high-potential startups across various industries globally. MassChallenge provides expert mentorship, a tailored curriculum, and access to corporate partners without taking any equity from the startups. Its programs, including specialized initiatives like MassChallenge FinTech and MassChallenge HealthTech, aim to facilitate partnerships between startups and established companies to drive innovation and growth. To date, MassChallenge has helped over 1,200 alumni raise more than $2 billion in funding and create over 65,000 jobs, demonstrating its significant impact on the global innovation ecosystem.

Cait Brumme

Acting CEO

Cait Brumme

Managing Partner

Siobhan Dullea

CEO

Matt Lashmar

Managing Director

Camila Lecaros

Managing Director

Yonit Serkin

Managing Director

Devon Sherman

Founding Director, Head of MassChallenge FinTech

Michelle Williams

Vice President and Head of Texas Strategy

Past deals in Copenhagen

Sparrow Quantum

Non Equity Assistance in 2021
Sparrow Quantum A/S is a privately held company that develops and commercializes photonic quantum technology components based on research and patents developed in the Niels Bohr Institute Quantum Photonics Lab. The Niels Bohr Institute’s Quantum Photonics Lab, headed by professor Peter Lodahl, is part of the Danish Center for Quantum Innovation, Qubiz, funded by Innovation Fund Denmark –– a national large scale investment in quantum technologies.

Octarine Bio

Non Equity Assistance in 2020
Octarine Bio is a biotechnology company based in Copenhagen, Denmark, founded in 2018. The company specializes in the research and development of cannabinoid and psilocybin derivatives using synthetic biology. By employing a biosynthetic platform, Octarine Bio aims to create a range of natural and novel cannabinoid and psilocybin-derived molecules that possess enhanced pharmacokinetic and therapeutic properties. These advancements are designed to support healthcare professionals in treating neurological and psychological disorders, ultimately improving the health and well-being of individuals.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.